NIH is now enrolling older adults for phase 1 trials of COVID-19 vaccine
On April 17, the National Institute of Allergy and Infectious diseases (NIAID), USA, released a piece of news that they are enrolling older candidates (above the age of 55) for phase 1 of the clinical trial of their COVID-19 vaccine.
The trial had begun on March 16 and originally been designed to enrol about 45 individuals between the ages of 18 and 55. Now, the NIAID says that after the first enrollment they are set to enrol older candidates to get a better understanding of the effect of the vaccine and the immunological response against it.
Here is the timeline of the trial.
The first trial
On March 16, the National Institute of Allergy and Infectious diseases, USA, announced that they are beginning phase 1 trial of their COVID-19 vaccine. The clinical trial was to be done at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle and was to enrol 45 healthy candidates in the age group of 18 and 55. They had started recruiting people since March 3, 2020.
The vaccine under trial is an mRNA vaccine developed at Moderna Inc, a pharmaceutical company based in Massachusetts, USA. This vaccine uses pieces of mRNA (nucleic acid) that on being introduced in the body, produce specific viral proteins (but do not cause disease). Our immune system recognises these viral proteins and makes antibodies against them like it was the virus itself. These antibodies will protect against the SARS-CoV-2 virus if the person is exposed to it in a natural setting.
KPWHRI gave the first dose of the vaccine to volunteers in Seattle on March 16.
National Institute of Allergy and Infectious Diseases is an institute under the National Institute of Health, USA. It works for understanding and dealing with infections and allergies. The NIH is funding the Moderna research.
On March 27, NIH also added Emory University, Atlanta as their second site for phase 1 of the clinical trial of the same vaccine.
Both Kaiser and Emory are a part of the NIAID’s Infectious Diseases and Clinical Research Consortium. This consortium consists of all the units that work on the clinical trials of vaccines and treatments under the NIAID as well as a consortium leadership group that consists of investigators of the vaccine and other infectious disease experts.
Under the first trial, the 45 volunteers were to be given two shots of the mRNA vaccine one month apart and a third shot a year later.
The latest developments
After enrolling the first 45 candidates, the NIAID has now announced that they are expanding the original study to include 60 more people. Out of these 60, 30 volunteers would be in the age group of 56 to 70 years and the rest 30 would be above the age of 70.
As per the news release on the NIAID’s page, the trial on younger people have proven to be safe so far and they have not yet noticed any significant safety issues in young volunteers. Now, expanding the trial to include older volunteers would help the scientists to study the effects of the vaccine on the older people (the most high-risk group) and look for side effects, if any, in that age group.
With this trial, the NIH has also included another of its sites - Vaccine Research Center (VRC) clinic in Bethesda, Maryland - increasing the total testing sites to three.
All the three sites will now be enrolling candidates and once the enrollments are complete, all the volunteers would be given the Moderna vaccine as per the same schedule as was tested in younger adults - 2 doses one month apart and a third after a year.
The NIH will keep releasing all the data as soon as they can to make it available to public health officials and the scientific community.
For more information, read our article on WHO Solidarity Project to find a treatment for COVID-19.
Health articles in Firstpost are written by myUpchar.com, India’s first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.
Updated Date: Apr 21, 2020 14:37:21 IST
The information provided here is intended to provide free education about certain medical conditions and certain possible treatment. It is not a substitute for examination, diagnosis, treatment, and medical care provided by a licensed and qualified health professional. If you believe you, your child or someone you know suffers from the conditions described herein, please see your health care provider immediately. Do not attempt to treat yourself, your child, or anyone else without proper medical supervision. You acknowledge and agree that neither myUpchar nor firstpost is liable for any loss or damage which may be incurred by you as a result of the information provided here, or as a result of any reliance placed by you on the completeness, accuracy or existence of any information provided herein.
COVID-19 Social Distancing: Study suggests 6 feet is not enough, virus can travel up to 20 feet
When can India expect to achieve herd immunity?
International Women’s Health Day 2020: Eight sexual health commandments for every woman to live by
Hypertension: How a hormone called aldosterone may have been the cause of your high blood pressure
Review study suggests vitamin D may not be a predictor of COVID-19 deaths, unlike previously thought
Can artificial sunlight kill the COVID-19 causing virus?
Coronavirus Outbreak Updates: 2,091 people test positive for COVID-19 in Maharashtra today; confirmed cases rise to 54,758 in state
Coronavirus Outbreak Updates: Mumbai reports 1,382 new COVID-19 cases; confirmed infections rise to 25,317
Coronavirus Outbreak Updates: Junior assistant in Delhi LG's office tests positive for COVID-19; samples from 40 staff members taken
Coronavirus Outbreak Updates: 459 people test positive for COVID-19 in Pune today, total number of cases rises to 6,153
Coronavirus Outbreak Updates: Railways will partially restore train services from 1 June, says Centre; bookings for 200 trains to begin tomorrow
Coronavirus Outbreak Updates: 267 new COVID-19 patients reported in Rajasthan today, total number of cases rises to 6,494